Evidence map›Paper›PMID 37415371›Full record

ArticleCurrent diabetes reviews2024

Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors Prescription among Physicians in Saudi Arabia.

Mohammed Somaili, Omar Oraibia, Majed Darraj, Amal Hassan, Esaam Moafa, Abdulrahman Kulaybi, Sahar Shubayli, Razan Moafa, Ghadah Mghfori, Afaf Jaafari and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current diabetes reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohammed SomailiDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Omar OraibiaDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Majed DarrajDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Amal HassanDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Esaam MoafaDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Abdulrahman KulaybiDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Sahar ShubayliDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Razan MoafaDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Ghadah MghforiDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Afaf JaafariDepartment of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Majed SomilyMinistry of Health, Jazan, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSodium-glucose cotransporter 2 inhibitors are a new class of medications that have been proven to improve both glycemic control and cardio-renal outcomes. The knowledge, attitude, and perception toward their prescriptions in Jazan, Saudi Arabia, are still unknown.

objectiveThe study aimed to measure the level of knowledge and attitude toward sodium-glucose cotransporter 2 inhibitors prescription among physicians in the Jazan region, Saudi Arabia.

methodsData analysis was performed using Statistical Package for the Social Sciences, SPSS 23rd version. Frequency and percentages were used to display categorical variables. Minimum, maximum, mean, and standard deviation were used to test numerical variables. Independent t-test and ANOVA test were both utilized to test the factors associated with knowledge and attitude toward the use of SGLT-2 inhibitors.

resultsA total of 65 participants were included in the study. 26.2% had a low knowledge level, 30.8% had a moderate knowledge level, and 43.1% had a high knowledge level of sodium-glucose cotransporter 2 inhibitors. 9.2% had a low attitude level, 43.1% had a moderate attitude level, and 47.7% had a high attitude level toward sodium-glucose cotransporter 2 inhibitors. Age, professional status, years of experience, and specialty were significantly associated with attitude but not with the knowledge of sodium-glucose cotransporter 2 inhibitors prescription.

conclusionWhile the study cohort scored high in the knowledge and attitude domains of the survey, a large proportion failed to answer very essential questions in type 2 diabetes management. An educational awareness program needs to be carried out to strengthen the physicians' knowledge of SGLT2 inhibitors prescription.

Indexed as

Diabetes Mellitus, Type 2Health Knowledge, Attitudes, PracticePractice Patterns, Physicians'Sodium-Glucose Transporter 2 InhibitorsAdultAttitude of Health PersonnelCross-Sectional StudiesDrug PrescriptionsFemaleHumansHypoglycemic AgentsMaleMiddle AgedPhysiciansSaudi ArabiaSurveys and QuestionnairesHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsattitudeKnowledgesodium-glucose co-transporter inhibitorsstandard deviationtype 2 diabetes mellitus

Identifiers

PMID37415371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.